| 黄毅超,刘云军,高颜凤,陆小玲,柯彩屏.恩度胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水患者血清因子含量及临床疗效分析.[J].中南医学科学杂志.,2018,(2):180-182. |
| 恩度胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水患者血清因子含量及临床疗效分析 |
| The Analysis of pleural perfusion Endostar combined with cisplatin in the treatment of lung cancer patients with malignant pleural effusion by serum factor content and clinical efficacy |
| 投稿时间：2017-12-29 修订日期：2018-03-01 |
| DOI：10.15972/j.cnki.43-1509/r.2018.02.019 |
| 中文关键词: 恩度胸腔灌注 静脉顺铂化疗 肺癌 恶性胸腹水 生活质量 |
| 英文关键词:Endostar thoracic infusion intravenous chemotherapy lung cancer malignant ascites quality of life |
| 基金项目: |
|
| 摘要点击次数: 594 |
| 全文下载次数: 598 |
| 中文摘要: |
| 分析恩度胸腔灌注治疗肺癌所致的恶性胸腹水的临床疗效。记录治疗前、后患者临床症状的变化情况。治疗后缺氧诱导因子-1(HIF-1α)、血管内皮生长因子(VEGF)含量明显降低,生活质量评分增高。恩度胸腔灌注治疗肺癌所致的恶性胸腹水,能有效抑制HIF-1α、VEGF的表达含量,改善患者的生活质量,值得临床借鉴。 |
| 英文摘要: |
| To analyse the clinical efficacy of Endostar thoracic perfusion in the treatment of malignant pleural effusion caused by lung cancer. The contents of hypoxia inducible factor -1 (HIF-1α) and vascular endothelial growth factor (VEGF) were significantly decreased, and the HIF-1α and VEGF levels were lower. After treatment, the quality of life was better. Endostar thoracic perfusion in the treatment of malignant pleural effusions caused by lung cancer, the expression of the content can effectively inhibit HIF-1α, VEGF, improve the quality of life of patients, worthy of clinical reference. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|